Impact News +++ Carl Icahn′s top Q3 moves include new stake in EchoStar, exiting Bausch Health (SeekingAlpha) +++ ECHOSTAR Aktie -4,17%

VERRICA Aktie

>VERRICA Aktienkurs

3.44 EUR +3.6% (Tradegate)

Ask: 3.5 EUR / 852 Stück

Bid: 3.3 EUR / 912 Stück

Tagesumsatz: 1 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

VERRICA Aktie über LYNX handeln

Intraday

1 Jahr

>VERRICA Performance

1 Woche: +15,8%

1 Monat: +3,0%

3 Monate: -44,5%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>VERRICA Aktie

Name:

VERRICA PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US92511W2070 / A41A98

Symbol/ Ticker:

1NE0 (Frankfurt) / VRCA (NASDAQ)

Kürzel:

FRA:1NE0, ETR:1NE0, 1NE0:GR, NASDAQ:VRCA

Index:

Webseite:

https://verrica.com/

Profil:

Marktkapitalisierung:

31.95 Mio. EUR

Unternehmenswert:

52.16 Mio. EUR

Umsatz:

12.65 Mio. EUR

EBITDA:

-31.7 Mio. EUR

Nettogewinn:

-41.82 Mio. EUR

Gewinn je Aktie:

-7.14 EUR

Schulden:

33.47 Mio. EUR

Liquide Mittel:

13.25 Mio. EUR

Operativer Cashflow:

-41.72 Mio. EUR

Bargeldquote:

0.53

Umsatzwachstum:

5.72%

Gewinnwachstum:

44.09%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

VERRICA

Letzte Datenerhebung:

15.11.25

>VERRICA Kennzahlen

Aktien/ Unternehmen:

Aktien: 9.45 Mio. St.

Frei handelbar: 40.36%

Leerverk. Aktien: 4.44%

Rückkaufquote: -106.78%

Mitarbeiter: 71

Umsatz/Mitarb.: 0.09 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 315.61%

Bewertung:

KGV: -

KGV lG: -

KUV: 2.5

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 86.46%

Gewinnmarge: -330.52%

Operative Marge: -257.32%

Managementeffizenz:

Gesamtkaprendite: -106.68%

Eigenkaprendite: -

>VERRICA Peer Group

Es sind 599 Aktien bekannt.

>VERRICA Chart & Kurs - NASDAQ

>VERRICA News

14.11.25 - 22:57	Verrica Pharmaceuticals Non-GAAP EPS of $0.13, revenue of $14.3M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.25 - 22:09	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire EN)
	– Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue –...

10.11.25 - 07:00

New Phase II Study Data from Lytix Biopharma′s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide (Cision)

Oslo, Norway, November 10, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today announced that new immune response data on ruxotemitide (formerly LTX-315/VP-315) were presented on behalf of Verrica Pharmaceuticals at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland. The immunological analyses from Verrica's Phase II study in basal cell carcinoma (BCC) demonstrated strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, alongside a marked reduction in immunosuppressive T-regulatory cells in the...

20.10.25 - 22:18	Verrica-Aktie mit Kurssprung nach positivem EMA-Feedback zur Behandlung von Dellwarzen/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

20.10.25 - 22:09	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union (GlobeNewswire EN)
	– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required –...

08.10.25 - 07:06

Lytix Biopharma′s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 (Cision)

Oslo, Norway, October 8, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, is pleased to announce that its license partner Verrica Pharmaceuticals Inc. will present new data from its Phase II clinical trial of VP-315 (Ruxotemitide, formerly LTX-315) for the treatment of basal cell carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5–9, 2025 in National Harbor, Maryland, USA. VP-315 will be featured in both an oral and a poster presentation during the conference. The abstract, titled “Exploratory...

07.10.25 - 22:09

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire EN)

WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland....

19.09.25 - 14:03	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum (GlobeNewswire EN)
	– Approval triggers $10 million cash milestone payment to Verrica –...

02.09.25 - 13:03

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)

WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City....

20.08.25 - 08:18	XFRA: 1NE0: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN VERRICA PHARM. NEW O.N. 1NE0 US92511W2070 AB/FROM ONWARDS 20.08.2025...

13.08.25 - 05:00	Verrica Posts Profit in Fiscal Q2 (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.25 - 01:00	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
	Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +102.86% and +154.04%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.08.25 - 22:36	Verrica Pharmaceuticals Non-GAAP EPS of $0.25 beats by $1.08, revenue of $12.7M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 22:06	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire EN)
	– Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in milestone revenue from Torii Pharmaceutical –...

25.07.25 - 09:03	XFRA: 1NE0: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL VERRICA PHARM. NEW O.N. 1NE0 US92511W2070 BAW/UFN...

25.07.25 - 08:15	XFRA: INSTRUMENT_SUSPENSION - EQUBF_01 (XETRA)
	Instrument ID [24848947] (1NE0 - US92511W2070) suspended...

24.07.25 - 18:06	XFRA: ISIN Change (XETRA)
	Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US15117N6022 Imunon Inc. 24.07.2025 US15117N7012 Imunon Inc. 25.07.2025 Tausch 15:1 US92511W1080 Verrica Pharmaceuticals Inc. 24.07.2025 US92511W2070 Verrica Pharmaceuticals Inc. 25.07.2025 Tausch 10:1...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer ernten will, muß erst den Samen streuen. - William Shakespeare

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram